Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Merck & Co., Inc. (NYSE: MRK) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. Merck is a New Jersey–incorporated biopharmaceutical preparation manufacturer whose common stock and multiple series of notes are registered on the New York Stock Exchange, as reflected in its Form 8-K filings.
Through this page, readers can review Merck’s current and historical filings, including Form 8-K reports on material events such as public offerings of long-dated notes under its automatic shelf registration statement on Form S-3ASR and announcements of restructuring programs. Filings related to quarterly and annual results, such as earnings releases furnished on Form 8-K, give additional context on the company’s financial condition and performance.
For a research-intensive company like Merck, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) are key sources for information on its human health and animal health businesses, major products like KEYTRUDA and GARDASIL, pipeline programs including WINREVAIR and Alzheimer’s disease candidates, risk factors and capital structure. Forms 3, 4 and 5, when filed, provide details on insider transactions by directors and officers.
Stock Titan enhances these filings with AI-generated explanations that highlight important sections, clarify technical language and point out items that may interest investors, such as new debt issuances, restructuring charges or significant acquisitions. Real-time updates from EDGAR help ensure that newly filed Merck documents, including 10-Ks, 10-Qs and Form 4 insider reports, appear promptly, allowing users to track regulatory disclosures related to MRK in a single, organized feed.
Merck & Co., Inc. executive vice president and general counsel Jennifer Zachary reported option exercises and related share sales in company stock. On 02/09/2026, she exercised three stock option grants covering 25,946, 56,792 and 38,835 shares of common stock, which had previously vested in scheduled installments. On the same date, she sold corresponding amounts of Merck common shares at a weighted average price of $119.1522 per share, with individual sale prices ranging from $118.9600 to $119.5100. Following these transactions, she directly held 68,915.671 shares of Merck common stock.
A shareholder has filed a notice of proposed sale of 37,685 shares of common stock, with an aggregate market value of $4,557,024.71. The shares are expected to be sold on or about 02/06/2026 on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.
The securities to be sold were acquired as restricted stock vesting under a registered plan from the issuer on several dates in 2024, including 21,845 shares on 01/22/2024 and 13,766 shares on 05/04/2024. By signing the notice, the selling person represents they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
An insider of the issuer has filed a Form 144 notice to sell 5,000 shares of common stock. The planned sale, through Morgan Stanley Smith Barney LLC on the NYSE, has an aggregate market value of $609,525.00 and an approximate sale date of February 6, 2026.
The 5,000 shares were acquired on February 6, 2026 by exercising options under a registered plan, paid for in cash. The filing notes that 2,482,022,536 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
Merck & Co., Inc. executive David Michael Williams reported an option exercise and share sale. On February 6, 2026, he exercised 5,000 stock options at $77.62 per share, receiving 5,000 shares of common stock, and then sold 5,000 common shares at $121.905 per share. Following these transactions, he directly owned 30,837.743 shares of Merck common stock and held 4,600 stock options.
MRK had a Rule 144 notice filed for a planned sale of 15,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of 1,827,991.50. The filing lists 2,482,022,536 shares of common stock outstanding.
The shares to be sold were acquired mainly through restricted stock vesting under a registered plan on multiple dates between May 2022 and January 2025, plus a small private acquisition from the issuer. The signer represents they are not aware of undisclosed material adverse information about the issuer.
Merck & Co., Inc. senior vice president of finance and global controller Dalton E. Smart III reported exercising stock options and selling shares of common stock. On 02/04/2026, he exercised an option for 4,000 shares of Merck common stock at an exercise price of $62.07 per share.
On the same date, Smart reported selling 4,000 Merck common shares at $119.675 per share, followed by an additional sale of 2,400 shares at the same price. After these transactions, he directly owned 8,204.816 shares of Merck common stock. The option originally vested in three equal annual installments beginning in 2018.
Merck & Co., Inc. President, U.S. Market, Johannes Jacobus Oosthuizen reported selling 15,000 shares of Merck common stock on February 6, 2026 at a weighted average price of $121.8661 per share. The sale occurred in multiple trades between $121.8200 and $121.9500. After this transaction, he directly beneficially owned 21,197.389 Merck shares.
Merck & Co., Inc. executive vice president and CFO Caroline Litchfield reported an option exercise and share sale. On February 4, 2026, she exercised 41,997 stock options at an exercise price of $53.06 per share, receiving the same number of common shares.
On the same date, she sold 41,997 Merck common shares at a weighted average price of $119.6112 per share, in multiple trades between $119.5400 and $119.7800. After these transactions, she directly owned 90,192.194 Merck common shares.
Merck & Co., Inc. executive Dean Y. Li reported an option exercise and share sale. On 02/04/2026 he exercised a stock option for 15,087 shares of common stock at an exercise price of $56.04 per share, increasing his direct holdings to 117,357.05 shares.
That same day, he sold 15,087 shares of Merck common stock at a weighted average price of $118.7661 per share, in multiple trades between $118.7200 and $118.8300. After the sale, he directly owned 102,270.05 Merck shares.
Merck & Co., Inc. executive stock sale: Chief Marketing Officer Chirfi Guindo sold 20,000 shares of Merck common stock on February 5, 2026 in an open-market transaction. The weighted average sale price was $121.8838 per share, with individual trades ranging from $121.84 to $121.97.
After this sale, Guindo still directly owns 80,615.127 Merck shares, so he remains a significant internal shareholder. The filing notes that detailed trade prices within the reported range are available on request from Merck, its security holders, or the SEC staff.